Post Ebos Group's H1 release, Ord Minnett has retained its $28.50 fair value estimate as the broker continues to believe the market is too confident about this company's outlook, despite the pending loss of the Chemist Warehouse contract.

Ebos Group still sits head and shoulders above its competitors, acknowledges the broker, but the pharma distribution business is facing challenges.

Ord Minnett has turned slightly more optimistic on institutional healthcare, but the negative offset has come via higher rental expenses. Earnings forecasts are largely unchanged.

Sector: Health Care Equipment & Services.

Target price is $28.50.Current Price is $34.93. Difference: ($6.43) - (brackets indicate current price is over target). If EBO meets the Ord Minnett target it will return approximately -23% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2024 Acquisdata Pty Ltd., source FN Arena